Major Outcomes With Personalized Dialysate TEMPerature

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-03

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People with failed kidneys need an artificial kidney machine (called dialysis) to remove toxins and extra fluid from the body. Most patients receive dialysis treatments at a hospital three times a week. During treatment, a patient's blood pressure may drop, causing dizziness and muscle cramping. Repeated drops in blood pressure can also injure the heart and brain. Over time, this can lead to heart attacks, strokes, and sometimes death due to cardiovascular causes. New research shows that cooling the temperature of the dialysis fluid (called dialysate) can reduce heart and brain injury. In most hospitals, all patients' dialysate temperature is set at 36.5 ºC (to match body temperature). In a study of 73 patients, we showed that reducing the dialysate temperature by 0.5 ºC below body temperature protected the heart and brain from injury \[1,2\]. We now want to test this simple, safe, low-cost intervention in a large study with \~7500 dialysis patients in Ontario. We can lower the dialysate temperature on dialysis machines in Ontario at no added cost. This intervention has the potential to reduce many hospitalizations and deaths in Ontario, and relieve suffering in patients with kidney failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control

NCT00759967

End Stage Renal Disease

COMPLETED NA

Feasibility of a Randomized Cluster Trial for Blood Pressure Targets in In-centre Hemodialysis Units

NCT06695611

Chronic Kidney Disease 5D

NOT_YET_RECRUITING NA

Remote Ischaemic Preconditioning to Prevent Dialysis Induced Cardiac Injury

NCT02630355

Hemodialysis Cardiovascular Diseases

TERMINATED PHASE2

Virtual Ward for Home Dialysis

NCT01912001

End Stage Renal Disease Kidney Failure Home Dialysis

COMPLETED NA

Assessment of a Wearable Ultrafiltration Device

NCT06832696

Hemodialysis Ultrafiltration

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Statement of the health problem or issue

Dialysis is a life-saving treatment for patients with kidney failure. However, over 20% of patients die within one year of starting dialysis from heart disease or stroke.

One reason that so many dialysis patients die from heart diseases and strokes may be related to the dialysis treatment itself. During dialysis, blood pressure often drops, and the flow of blood and oxygen to the heart and brain is reduced. Over time, this can cause significant damage to vital organs and result in heart attacks, strokes, and even death due to cardiovascular-related causes.

Our team was the first to show that the heart and brain become starved of blood and oxygen during dialysis. We and others have shown that lowering the temperature of dialysis (to just below the patient's own body temperature) improves blood flow and protects the heart and brain during dialysis. We will now determine if this method can prevent heart attacks and strokes in a large population of dialysis patients.
2. Objective of your project

The purpose of this study is to test the effect of outpatient hemodialysis centers randomized to (1) a personalized temperature-reduced dialysate protocol or (2) a standard-temperature dialysate protocol for 4 years on cardiovascular-related death and hospitalizations.
3. How will you undertake your work?

We will conduct a cluster randomized controlled trial. Our study will include \~7500 dialysis patients in 84 dialysis centres across Ontario. The name of this study is MyTEMP. Patients in 42 of the 84 dialysis centres will be in the treatment group and they will receive personalized dialysis (0.5-0.9ºC below their measured body temperature). Patients in the other 42 centres will be in the control group and will receive standard dialysis at a fixed temperature of 36.5ºC. This study will last for four years. At the end of four years, we will compare the rate of cardiovascular-related deaths, heart attacks, strokes, and heart failure in the treatment and control groups.
4. What is unique/innovative about your project?

We usually need to study a large number of patients in a clinical trial to reliably understand the effects of treatment. Normally, a study with 7500 patients would cost more than $15 million dollars to conduct; however, our study will provide a reliable answer to the question being asked and cost less than $2 million. This is because we will use data that is already being collected by our healthcare system. For example, when a patient is hospitalized for a heart attack or stroke, this information is recorded in a secure healthcare database. We will be able to analyze these healthcare data at the end of the study (and link patient outcomes to the type of dialysis treatment received (i.e. treatment or control)). This innovative study design means that our study will be much larger (but cost much less) than a traditional clinical trial.

This pragmatic trial includes all patients who receive chronic in-centre hemodialysis patients in participating Ontario centres. High-risk patients with multiple comorbidities, including cognitive impairments or disabilities, who are often excluded from trials because of their high-risk status are eligible for participation in the MyTEMP trial. By including patients from a variety of medical, ethnic, geographic, and socioeconomic backgrounds, the results of our trial should be broadly generalizable.
5. What is the impact of the proposed research?

Currently, many patients worldwide receive hemodialysis with a dialysate temperature of 36.5ºC to 37.0ºC. Lowering the dialysate temperature below a core body temperature is a promising intervention that has the potential to reduce the risk of cardiovascular-related mortality and major adverse cardiovascular events in patients on hemodialysis.

At four years of follow-up, our trial is powered to detect a minimum 20% hazard rate difference in the composite outcome of time to first cardiovascular-related mortality or hospitalization for major cardiovascular events among centres that use a temperature-reduced personalized hemodialysis protocol compared with centres that use a standard-temperature hemodialysis protocol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Diseases End-Stage Kidney Disease Hemodialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Personalized Dialysate Temperature

Dialysis centres randomized to the intervention arm will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.

Group Type EXPERIMENTAL

Personalized Dialysate Temperature

Intervention Type OTHER

Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.

Fixed Dialysate Temperature at 36.5°C

Dialysis centres in the control group will provide usual care, which is standard dialysis using a fixed dialysate temperature of 36.5°C

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Personalized Dialysate Temperature

Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Individualized Dialysate Temperature

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The hemodialysis centre must have cared for a minimum of 15 outpatients being treated with maintenance in-centre hemodialysis on January 1st, 2017.
* The medical director of the hemodialysis centre (who acted as the centre's gatekeeper) must have been willing for their centre to adopt the randomly allocated dialysate temperature protocol for the duration of the trial.